Peptide Drug

DRAVP ID DRAVPc069

Name Asunaprevir

Sequence Not available

Molecular Formula C35H46ClN5O9S

Condition/Disease hepatitis C genotype 1b

Group Approved, Investigational, Withdrawn

Type peptide

Description Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.

Active sequence/Structure

DrugBank Accession Number DB11586

Pubchem ID 16076883

CHEMBL ID CHEMBL2105735

UNII S9X0KRJ00S

CAS 630420-16-5

Reference 25061308 22508297 22256805

NCT Number	Study Title	Condition/Disease	Status	Phase	Sponsor
NCT00940771	Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens	Pediatric HIV; HIV Infections	Completed	Phase 4	Phoenix Children's Hospital
NCT01511809	Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression	HIV-1 Infection	Completed	Phase 3	IRCCS San Raffaele
NCT00307502	Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV	HIV Infections	Completed	Phase 1	Germans Trias i Pujol Hospital

NCT Number

Study Title

Condition/Disease

Status

Phase

Sponsor

NCT00940771

Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens

Pediatric HIV; HIV Infections

Completed

Phase 4

Phoenix Children's Hospital

NCT01511809

Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression

HIV-1 Infection

Completed

Phase 3

IRCCS San Raffaele

NCT00307502

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

HIV Infections

Completed

Phase 1

Germans Trias i Pujol Hospital